# New clinical trials in Mexico: 570 since Nov 2024

Updated November 9, 2026.

570 clinical studies with a site in Mexico were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 264 have an industry sponsor and 329 are recruiting or about to. The newest, NCT07926750, was posted on November 9, 2026: Community Context and Psychological Flexibility in Residential Substance Use Treatment: A Longitudinal... (Under The Tree Therapeutic Community).

## The full list

New clinical trials with a site in Mexico: 570 rows for $28.50, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 19 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/country/mexico

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 570
- Industry sponsored: 264
- Recruiting or not yet: 329
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 570, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926750 | Community Context and Psychological Flexibility in Residential Substance Use Treatment: A Longitudinal Sequential Mediation Study | Under The Tree Therapeutic Community | Observational | Active not recruiting | Substance-Related Disorders, Substance Use Disorders | 80 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926750) |
| November 9, 2026 | NCT07926321 | A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment | Boehringer Ingelheim | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 70 | Belgium, Finland, Germany, Japan, Mexico, South Korea, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926321) |
| November 9, 2026 | NCT07924150 | CLUSTER TRAINING + CREATINE PROJECT | Dynamical Business and Science Society - DBSS International SAS | Not applicable | Completed | Sarcopenia in Elderly, Creatine Supplementation, Resistance Exercise | 28 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924150) |
| November 9, 2026 | NCT07924020 | Acute Effects of Rhodiola Rosea and Caffeine on Mean Propulsive Velocity Loss in Resistance Training | MARINA MEDINA CORRALES | Not applicable | Not yet recruiting | Muscle Fatigue (C23.888.592.612.612) | 20 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924020) |
| November 4, 2026 | NCT07915219 | A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Bronchiectasis | 1,500 | Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915219) |
| November 3, 2026 | NCT07911696 | Comparative Effectiveness and Safety of Two Hyaluronic Acid Products in Knee Osteoarthritis | Coordinación de Investigación en Salud, Mexico | Observational | Not yet recruiting | Osteoarthritis, Knee | 160 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911696) |
| November 2, 2026 | NCT07909616 | Respiratory Physiotherapy and Inflammatory Biomarkers in Critically Ill Patients With Pneumonia | Hospital H+ Queretaro | Observational | Recruiting | Pneumonia, Critical Illness | 180 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909616) |
| October 30, 2026 | NCT07907666 | Ropivacaine Alone Versus Ropivacaine Plus Lidocaine With or Without Epinephrine for Supraclavicular Brachial Plexus Block in Upper Limb... | Instituto Mexicano del Seguro Social | Phase 4 | Completed | Postoperative Pain, Upper Extremity Fracture, Anesthesia, Conduction | 138 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907666) |
| October 29, 2026 | NCT07905755 | Effect of HMB Supplementation and Vivifrail Exercise on Body Composition, Handgrip Strength and Physical Performance in Women Over 60 Years... | Universidad Autónoma del Estado de Hidalgo | Not applicable | Not yet recruiting | Aging, Muscle Strength, Physical Functional Performance, Body Composition | 44 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905755) |
| October 28, 2026 | NCT07901894 | Study to Evaluate the Efficacy and Safety of Dexketoprofen / Butylscopolamine vs Dexketoprofen in Treatment of Primary Dysmenorrhea | Laboratorios Silanes S.A. de C.V. | Phase 3 | Completed | Primary Dysmenorrhea | 130 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901894) |
| October 28, 2026 | NCT07901140 | Adverse Events During Physical Therapy in Neurocritical ICU Patients | Hospital H+ Queretaro | Observational | Active not recruiting | Critical Illness, Brain Injury, Stroke, Subarachnoid Hemorrhage, Brain Neoplasms, Orthostatic Intolerance | 47 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901140) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 26, 2026 | NCT07893717 | Motivational Interviewing Intervention for Families With Overweight and Obesity | Universidad Autonoma de Baja California | Not applicable | Active not recruiting | Obesity & Overweight | 120 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893717) |
| October 26, 2026 | NCT07893704 | Aortic Size and Height Indices in Abdominal Aortic Aneurysms | Tecnologico de Monterrey | Observational | Not yet recruiting | Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm, Ruptured, Abdominal Aortic Aneurysm Without Rupture | 2,000 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893704) |
| October 22, 2026 | NCT07890025 | CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study | Hospital Universitario Dr. Jose E. Gonzalez | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 30 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890025) |
| October 21, 2026 | NCT07886268 | A Study to Evaluate the Efficacy and Safety of TP-06 for PCED | Tarsus Pharmaceuticals, Inc. | Phase 2 | Recruiting | Persistent Corneal Epithelial Defect | 32 | Dominican Republic, El Salvador, Mexico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886268) |
| October 19, 2026 | NCT07881185 | Artificial Intelligence for Brain MRI Analysis in Epilepsy | Istituto Giannina Gaslini | Observational | Recruiting | Epilepsies | 2,000 | Australia, Belgium, Brazil, Canada, China, Germany, Italy, Mexico, South... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881185) |
| October 16, 2026 | NCT07877545 | Egg Albumin and Agave Fructans With Exercise in Hemodialysis | Centenario Hospital Miguel Hidalgo | Not applicable | Active not recruiting | Sarcopenia, Chronic Kidney Disease, Hemodialysis | 66 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877545) |
| October 15, 2026 | NCT07875088 | Real-World Outcomes of Drug-Coated Balloon Angioplasty in Coronary Artery Disease | Kristian Rivera | Observational | Recruiting | Coronary Artery Disease | 2,000 | Mexico, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875088) |
| October 15, 2026 | NCT07874958 | "AFRONTA Emotional Care" Intervention for Family Caregivers of Children With Cancer. | Universidad de Guanajuato | Not applicable | Completed | Caregiver Burden, Child, Cancer | 14 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874958) |
| October 13, 2026 | NCT07871617 | Prophylactic TAP Block in Laparoscopic Cholecystectomy | Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo | Not applicable | Completed | Cholecystitis | 60 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871617) |
| October 13, 2026 | NCT07870668 | Intermittent Phentermine for Obesity and Body Composition | OSCAR MANUEL TORRES FALCON | Phase 4 | Completed | Obesity & Overweight | 600 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870668) |
| October 7, 2026 | NCT07863674 | Cardiovascular Risk Factors in Mexican Women | Medicaweb, S.A.C.V. | Observational | Not yet recruiting | Cardiovascular Risk Factors, Cardiovascular Diseases | 3,000 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863674) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |
| October 2, 2026 | NCT07856199 | Pudendal Atherosclerosis by IVUS-NIRS in Men With Coronary Artery Disease | Hospital Central Militar | Not applicable | Recruiting | Coronary Artery Disease, Erectile Dysfunction, Atherosclerosis | 60 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856199) |
| September 30, 2026 | NCT07850765 | Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets | Novo Nordisk A/S | Observational | Completed | Overweight, Obesity | 1,260 | Israel, Mexico, Saudi Arabia, South Africa, Turkey (Türkiye), United Arab... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850765) |
| September 29, 2026 | NCT07847645 | Feasibility of a Healthy Lifestyle Program (Athletes for Life) in Mexicali, Baja California | Universidad Autonoma de Baja California | Not applicable | Completed | Obesity Prevention, Healthy Lifestyle Behaviors | 14 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847645) |
| September 25, 2026 | NCT07841015 | A Study to Learn More About How Well Finerenone Works in Real-world in People With Type 2 Diabetes and Chronic Kidney Disease in Primary... | Bayer | Observational | Not yet recruiting | Type 2 Diabetes, Chronic Kidney Disease (CKD) Stages G2 to G3b | 800 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841015) |
| September 24, 2026 | NCT07837856 | Therapeutic Adherence in Type 2 Diabetes | Instituto Mexicano del Seguro Social | Not applicable | Completed | Diabetes Mellitus, Type 2/Prevention & Control, Diabete Type 2, Treatment Adherence | 250 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837856) |
| September 22, 2026 | NCT07835360 | Body Composition Changes After Initiation of GLP-1 Receptor Agonists in Adults With Obesity or Type 2 Diabetes | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Observational | Recruiting | Obesity (Disorder), Type 2 Diabetes Mellitus | 200 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07835360) |
| September 18, 2026 | NCT07828990 | Cardiovascular Risk Factors and Lipid Profile in Hospitalized Mexican Adults | Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo | Observational | Completed | Dyslipidemia | 107 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828990) |
| September 18, 2026 | NCT07828093 | Effect of Agave Consumption on Performance and Gut Microbiota in Adults Undergoing Physical Training | National Polytechnic Institute, Mexico | Not applicable | Enrolling by invitation | Dysbiosis | 12 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828093) |
| September 15, 2026 | NCT07820579 | Sirolimus Treatment in Pediatric Patients With Ataxia-Telangiectasia | Sara Elva Espinosa Padilla, MD | Phase 2 | Completed | Ataxia-Telangiectasia (A-T), Ataxia-Telangiectasia | 6 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07820579) |
| September 14, 2026 | NCT07818369 | Synbiotic LA-5 and Agave Inulin for Mild Cognitive Impairment | Anahuac University | Not applicable | Recruiting | Cognitive Impairment | 20 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818369) |
| September 14, 2026 | NCT07817875 | Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12... | Eli Lilly and Company | Phase 3 | Recruiting | Obesity | 150 | Belgium, Israel, Italy, Mexico, Poland, Portugal, South Korea, Spain, Taiwan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817875) |
| September 14, 2026 | NCT07816679 | GDS Method for Frozen Shoulder | Anahuac University | Not applicable | Completed | Adhesive Capsulitis, Frozen Shoulder | 30 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816679) |
| September 11, 2026 | NCT07815743 | Meniscal Repair Augmented With Leukocyte-Poor Platelet-Rich Plasma: A Prospective Comparative Clinical Study | Universidad Autonoma de Nuevo Leon | Not applicable | Not yet recruiting | Meniscal Tears | 62 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815743) |
| September 10, 2026 | NCT07813520 | Effect of an ACT-based Intervention to Reduce Anxiety in Medical Students | University of Guadalajara | Not applicable | Completed | Anxiety, Somatization, Depressive Symptom, Stress (Psychology) | 135 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813520) |
| September 9, 2026 | NCT07811193 | A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With... | Vividion Therapeutics, Inc. | Phase 2 | Recruiting | Colorectal Adenocarcinoma | 140 | Argentina, Belgium, Brazil, China, France, Germany, Greece, Hong Kong, Italy... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811193) |
| September 9, 2026 | NCT07810517 | Lactobacillus Acidophilus and Inulin for Cognitive Impairment in Obesity | Anahuac University | Not applicable | Recruiting | Obesity (Disorder) | 40 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07810517) |
| September 9, 2026 | NCT07808697 | A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to \<12 Years of Age | ModernaTX, Inc. | Phase 2 | Recruiting | SARS-CoV-2 | 300 | Argentina, Dominican Republic, Mexico, Panama, Puerto Rico, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808697) |
| September 8, 2026 | NCT07807189 | HERMES: International Survey and Portable External Power Evaluation During Respiratory Support Transport | Medipol University | Observational | Completed | Patient Transport, Respiratory Failure, Noninvasive Ventilation, High-Flow Nasal Oxygen, Mechanical Ventilation... | 246 | Chile, Croatia, Egypt, India, Iran, Italy, Mexico, Oman, Qatar, Saudi Arabia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807189) |
| September 4, 2026 | NCT07805655 | Radiofrequency Treatment Versus Topical Therapy for Facial Acne Vulgaris | Jeisys Medical Inc | Not applicable | Recruiting | Acne Vulgaris | 60 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805655) |
| September 3, 2026 | NCT07802431 | Clinical Evaluation of Linear Z for Body Contouring | Jeisys Medical Inc | Not applicable | Recruiting | Non Invasive Body Contouring | 30 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802431) |
| September 1, 2026 | NCT07797335 | AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People... | Novo Nordisk A/S | Phase 3 | Recruiting | Type 2 Diabetes, Cardiovascular Risk | 1,778 | Argentina, Brazil, Bulgaria, Canada, China, Czechia, Germany, Greece, India... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07797335) |
| August 31, 2026 | NCT07794579 | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1... | Eli Lilly and Company | Phase 3 | Recruiting | Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal | 2,001 | Argentina, China, Czechia, Germany, India, Japan, Mexico, Puerto Rico, South... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794579) |
| August 27, 2026 | NCT07789015 | A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Idiopathic Inflammatory Myopathies | 270 | Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789015) |
| August 26, 2026 | NCT07787897 | Ultra-low Split-dose Oral Lactulose vs High-volume Split-dose Polyethylene Glycol as Bowel Preparation for Outpatient Colonoscopies. | National Institute of Medical Sciences and Nutrition, Salvador Zubiran | Not applicable | Completed | Colonoscopy | 200 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07787897) |
| August 24, 2026 | NCT07782411 | Effect of Tocopherol and Ascorbic Acid on Neuroinflammation Markers Associated With Neuropeptide Expression in the AgRP/NPY and POMC... | Autonomous University of Morelos | Not applicable | Not yet recruiting | Obesity (BMI\>30), Neuroinflammation | 192 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782411) |
| August 20, 2026 | NCT07775300 | A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder | Eli Lilly and Company | Phase 3 | Recruiting | Depressive Disorder, Major | 1,000 | Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775300) |
| August 18, 2026 | NCT07771400 | Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtients | Latin American Cooperative Oncology Group | Observational | Not yet recruiting | Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage III... | 320 | Argentina, Brazil, Colombia, Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771400) |
| August 17, 2026 | NCT07767838 | Nipple Reinnervation in Two-stage Alloplastic Breast Reconstruction. | Hospital Angeles del Pedregal | Not applicable | Completed | Breast Reconstruction | 18 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07767838) |
| August 13, 2026 | NCT07763964 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100... | ADIUM | Not applicable | Completed | Bioequivalance | 46 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763964) |
| August 13, 2026 | NCT07763951 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100... | ADIUM | Not applicable | Completed | Bioequivalance | 46 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763951) |
| August 13, 2026 | NCT07763912 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50... | ADIUM | Not applicable | Completed | Bioequivalence | 46 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763912) |
| August 13, 2026 | NCT07763899 | Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50... | ADIUM | Not applicable | Completed | Bioequivalance | 46 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763899) |
| August 12, 2026 | NCT07761832 | Hemoglobin Trends as a Predictor of Outcomes in Critically Ill Patients (The TRENT-ICU Study) | Hospital H+ Queretaro | Observational | Completed | Critical Illness, Anemia | 128 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761832) |
| August 12, 2026 | NCT07761481 | CT-Determined Sarcopenia and Mortality in Critically Ill Cancer Patients | Hospital H+ Queretaro | Observational | Completed | Sarcopenia, Cancer, Critical Illness, Malnutrition | 23 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761481) |
| August 12, 2026 | NCT07761468 | Standardization of IMT Dosage (UTIT) in Mechanical Ventilation. | Hospital H+ Queretaro | Not applicable | Enrolling by invitation | Ventilator Induced Diaphragm Dysfunction, Respiratory Muscle Weakness, Mechanical Ventilation Weaning | 60 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761468) |
| August 12, 2026 | NCT07761364 | Physiological Changes in Adult Intensive Care Patients Following Contact With Their Primary Caregiver | Universidad Autonoma del Estado de Mexico | Not applicable | Recruiting | Critical Illness, Critically Ill Patients | 80 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761364) |
| August 12, 2026 | NCT07761117 | A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF | AstraZeneca | Phase 3 | Recruiting | Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF) | 6,950 | Argentina, Australia, Austria, Brazil, Bulgaria, Canada, China, Czechia... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761117) |
| August 12, 2026 | NCT07760883 | Metformin Effects According to SLC16A11 Carrier Status | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Observational | Recruiting | Diabetes Type 2 | 154 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760883) |
| August 12, 2026 | NCT07759245 | A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) | Eli Lilly and Company | Phase 2 | Recruiting | Pulmonary Disease, Chronic Obstructive | 606 | Argentina, Austria, Canada, China, Czechia, Denmark, France, Germany, Hungary... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759245) |
| August 11, 2026 | NCT07758933 | Safety of Lactobacillus LB Postbiotic in Immunocompromised Paediatric Patients With Diarrhoeal Disease | Hospital Infantil de Mexico Federico Gomez | Phase 1/2 | Not yet recruiting | Diarrhea | 30 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07758933) |
| August 10, 2026 | NCT07753993 | A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | AstraZeneca | Phase 3 | Recruiting | Chronic Kidney Disease | 7,000 | Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753993) |
| July 29, 2026 | NCT07734298 | Ultrasound vs. Nasofibroscopy for Evaluating Dysphagia After Extubation in the ICU | Hospital H+ Queretaro | Not applicable | Recruiting | Swallowing Disorders, Aspiration | 40 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734298) |
| July 28, 2026 | NCT07731503 | Conventional Versus Computer-Assisted Dental Anesthesia | University of Montemorelos | Not applicable | Completed | Anesthesia, Local | 29 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07731503) |
| July 27, 2026 | NCT07727954 | Efficacy and Safety of a Combined Topical Formula Versus Placebo in Patients With Melasma | University of Guadalajara | Not applicable | Completed | Melasma | 40 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727954) |
| July 27, 2026 | NCT07727018 | Clinical Trial of "Exploradores de Sabores" to Improve Food Selectivity in ASD Kids | Universidad Autonoma de Baja California | Not applicable | Recruiting | Autism Spectrum Disorder, Food Selectivity | 72 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727018) |
| July 23, 2026 | NCT07723196 | Effect of a Low AGE Diet on Liver Function in Adults With Fatty Liver. | Universidad de Guanajuato | Not applicable | Not yet recruiting | MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) | 48 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07723196) |
| July 23, 2026 | NCT07722650 | Twice-Daily Systane Complete Versus Four-Times-Daily Thealoz Duo for Dry Eye Disease | Instituto Internacional de Medicina y Terapia (IIMET) | Not applicable | Completed | Dry Eye Syndrome (DES), Ocular Surface Disease | 120 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722650) |
| July 20, 2026 | NCT07713693 | Dysphagia and Dysphonia in Anterior Cervical Spinal Surgery | Instituto Nacional de Rehabilitacion | Not applicable | Completed | Dysphonia, Dysphagia | 36 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713693) |
| July 20, 2026 | NCT07713446 | Effects of Task-Oriented Sit-to-Stand Training Using Immersive VR and PNF on Quality of Life in Chronic Stroke: Trial Protocol | Universidad Nacional Autonoma de Mexico | Not applicable | Not yet recruiting | Stroke, Cerebrovascular Accident (Stroke) | 93 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713446) |
| July 16, 2026 | NCT07708831 | Trial on Single/Multiple Ascending Doses for Safety, PK and PD for CBP-0276 in Healthy Subjects | Clarent Biopharma, Inc. | Phase 1 | Completed | Healthy Volunteers | 64 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708831) |
| July 15, 2026 | NCT07706530 | Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA) | Clarent Biopharma, Inc. | Phase 2 | Not yet recruiting | Arthritic Psoriasis | 240 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07706530) |
| July 15, 2026 | NCT07705269 | The FILTRATE Trial: High-Rate Ultrafiltration for Intravascular Congestion | Universidad Autonoma de Nuevo Leon | Not applicable | Recruiting | End Stage Chronic Renal Failure, Congestive Heart Failure (CHF), Intravascular Congestion, Fluid Overload | 70 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705269) |
| July 15, 2026 | NCT07705061 | Hertel Exophthalmometry Values in Mexican Adults | Instituto de Oftalmología Fundación Conde de Valenciana | Observational | Recruiting | Exophthalmometry, Normal Exophthalmometric Values | 300 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705061) |
| July 13, 2026 | NCT07698938 | The Safety and Microbial Changes in the Use of Intranasal Neosporin® | Hospital Universitario Dr. Jose E. Gonzalez | Not applicable | Completed | Teste the Safety of (Polymyxin B Sulfate 500,000 IU, Bacitracin Zinc 40,000 IU, Neomycin Sulfate 0.35g Neomycin Base)... | 12 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698938) |
| July 13, 2026 | NCT07698288 | Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fed... | ADIUM | Not applicable | Completed | Bioequivalence | 66 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698288) |
| July 13, 2026 | NCT07698275 | Clinical Study to Determine Bioequivalence of Oral Tamsulosin Products as 0.4 mg Prolonged-release Tablets in Male Subjects Under Fasted... | ADIUM | Not applicable | Completed | Bioequivalance | 34 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698275) |
| July 10, 2026 | NCT07696247 | Effect of Agave Inulin Supplementation on Metabolic Profile and Intestinal Abundance of Bifidobacterium and Lactobacillaceae in Adults With... | Universidad Autonoma de Queretaro | Not applicable | Active not recruiting | Type 2 Diabetes, Gut Microbiota, Insulin Resistance, Metabolic Syndrome, Prebiotic | 43 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07696247) |
| July 10, 2026 | NCT07694791 | Probiotic and Prebiotic Supplementation in Peritoneal Dialysis Patients | Hospital Universitario Dr. Jose E. Gonzalez | Not applicable | Recruiting | Chronic Kidney Disease (Stages 4 and 5), Peritoneal Dialysis (PD) | 60 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07694791) |
| July 9, 2026 | NCT07692009 | Collagen-PVP vs Hylan G-F 20 in the Treatment of Knee Osteoarthritis | Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan S. | Phase 4 | Completed | Osteoarthritis (OA) of the Knee | 32 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07692009) |
| July 9, 2026 | NCT07691970 | Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From... | AstraZeneca | Phase 3 | Recruiting | Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus | 1,072 | Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691970) |
| July 7, 2026 | NCT07688733 | Predicting Worsening Acute Kidney Injury With a Water-Pill (Furosemide) Test and Blood Markers in Patients With Low Albumin | Maithe Caroline Inacio | Not applicable | Completed | Acute Kidney Injury, Hypoalbuminemia | 55 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688733) |
| July 7, 2026 | NCT07687966 | CBP-0276 to Reduce Opioid Use in Adults Undergoing Major Orthopedic Surgery | Clarent Biopharma, Inc. | Phase 2 | Recruiting | Hip or Knee Replacement | 80 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687966) |
| July 6, 2026 | NCT07685392 | Progressive Strength and Balance Exercise for Fall Prevention in Postmenopausal Women With Osteoporosis | Instituto Nacional de Rehabilitacion | Not applicable | Completed | Postmenopausal Osteoporosis, Accidental Falls, Aged, Exercise Movement Techniques, Fragility Fractures | 46 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685392) |
| July 2, 2026 | NCT07680738 | Transcranial Direct Current Stimulation for Fatigue, Mood, and Cognition in Multiple Sclerosis | Universidad de Almeria | Not applicable | Completed | Multiple Sclerosis, MS, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS)... | 38 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680738) |
| July 1, 2026 | NCT07678671 | Glycemic Control and the Ask Me 3® Educational Program | Maria Elena Romero Ibarguengoitia | Not applicable | Enrolling by invitation | Diabetes Mellitus Type 2 | 250 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678671) |
| July 1, 2026 | NCT07678268 | Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir... | Instituto Mexicano del Seguro Social | Phase 4 | Recruiting | HIV Infection, Antiretroviral Therapy, Lentivirus Infections | 78 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678268) |
| July 1, 2026 | NCT07678203 | Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis | Hospital Civil Juan I. Menchaca | Phase 1/2 | Active not recruiting | Lupus Nephritis (LN), Chronic Kidney Disease, SGLT 2 Inhibitors, Systemic Lupus Erythematosus | 30 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07678203) |
| June 26, 2026 | NCT07671222 | Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease | Instituto de Oftalmología Fundación Conde de Valenciana | Phase 2 | Not yet recruiting | Sjogren Syndrome, Sjogren Syndrome With Keratoconjunctivitis, Dry Eye Disease (DED) | 38 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671222) |
| June 25, 2026 | NCT07668440 | The Effects, Usability, Satisfaction, Barriers, and Benefits of a Remote, Multidomain Website-based Intervention to Prevent Cognitive... | Instituto Mexicano del Seguro Social | Not applicable | Active not recruiting | Coginitive Dysfunction | 71 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668440) |
| June 25, 2026 | NCT07668336 | A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Diabetes Mellitus, Type 2 | 170 | Belgium, Brazil, India, Italy, Japan, Mexico, South Korea, Spain, Taiwan... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668336) |
| June 25, 2026 | NCT07667322 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation... | Hoffmann-La Roche | Phase 1 | Active not recruiting | Multiple Sclerosis | 75 | Brazil, Mexico, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667322) |
| June 24, 2026 | NCT07666815 | Intradialytic Exercise Combined With Creatine Monohydrate in Patients With Chronic Kidney Disease Undergoing Hemodialysis. | Pedro Julian Flores Moreno | Phase 1/2 | Recruiting | Chronic Kidney Disease 5D | 48 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07666815) |
| June 24, 2026 | NCT07665775 | Effectiveness of an Inpatient Rehabilitation and Prosthetic Training Model in Patients With Vascular and Metabolic Transfemoral Amputation | Instituto Nacional de Rehabilitacion | Observational | Not yet recruiting | Diabetes Mellitus, Transfemoral Amputation, Peripheral Arterial Disease, Vascular Thrombosis | 54 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07665775) |
| June 23, 2026 | NCT07662161 | Coronary Artery Calcium Score in HIV Mexican Population (The CACsHIVMex Study) | Instituto Mexicano del Seguro Social | Observational | Not yet recruiting | HIV - Human Immunodeficiency Virus | 384 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662161) |
| June 23, 2026 | NCT07662135 | A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and... | AstraZeneca | Phase 3 | Recruiting | Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease | 900 | Bulgaria, China, Denmark, Germany, India, Japan, Malaysia, Mexico, Spain... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662135) |
| June 23, 2026 | NCT07662109 | A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2... | AstraZeneca | Phase 3 | Recruiting | Type 2 Diabetes Mellitus | 2,000 | Argentina, Brazil, China, Czechia, Denmark, Germany, Greece, Hungary, India... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662109) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Eli Lilly and Company | 27 | October 28, 2026 |
| Instituto Mexicano del Seguro Social | 25 | October 30, 2026 |
| Instituto de Oftalmología Fundación Conde de Valenciana | 19 | July 15, 2026 |
| Boehringer Ingelheim | 18 | November 9, 2026 |
| AstraZeneca | 16 | August 12, 2026 |
| Hoffmann-La Roche | 16 | June 25, 2026 |
| Bristol-Myers Squibb | 15 | March 2, 2026 |
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 14 | September 22, 2026 |
| University of Guadalajara | 14 | September 10, 2026 |
| Merck Sharp & Dohme LLC | 14 | December 5, 2025 |
| ADIUM | 12 | August 13, 2026 |
| Hospital Universitario Dr. Jose E. Gonzalez | 11 | October 22, 2026 |
| Sanofi | 11 | September 24, 2025 |
| Hospital H+ Queretaro | 10 | November 2, 2026 |
| Pfizer | 10 | May 19, 2026 |
| Hospital Civil de Guadalajara | 10 | April 15, 2026 |
| Novartis Pharmaceuticals | 10 | April 8, 2026 |
| Universidad Autonoma de Baja California | 9 | October 26, 2026 |
| Universidad Autonoma de Nuevo Leon | 9 | September 11, 2026 |
| Coordinación de Investigación en Salud, Mexico | 8 | November 3, 2026 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Obesity](https://specstream.ai/data/clinical-trials/condition/obesity) | 50 | October 28, 2026 |
| [Diabetes Mellitus, Type 2](https://specstream.ai/data/clinical-trials/condition/diabetes-mellitus-type-2) | 31 | October 28, 2026 |
| [Overweight](https://specstream.ai/data/clinical-trials/condition/overweight) | 30 | October 28, 2026 |
| [Renal Insufficiency, Chronic](https://specstream.ai/data/clinical-trials/condition/renal-insufficiency-chronic) | 20 | October 16, 2026 |
| [Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/breast-neoplasms) | 13 | March 12, 2026 |
| [Carcinoma, Non-Small-Cell Lung](https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung) | 13 | January 23, 2026 |
| [Motor Activity](https://specstream.ai/data/clinical-trials/condition/motor-activity) | 11 | October 26, 2026 |
| [Inflammation](https://specstream.ai/data/clinical-trials/condition/inflammation) | 11 | October 16, 2026 |
| [Critical Illness](https://specstream.ai/data/clinical-trials/condition/critical-illness) | 10 | November 2, 2026 |
| [Diabetes Mellitus](https://specstream.ai/data/clinical-trials/condition/diabetes-mellitus) | 9 | September 24, 2026 |
| [Depression](https://specstream.ai/data/clinical-trials/condition/depression) | 9 | September 10, 2026 |
| [Hypertension](https://specstream.ai/data/clinical-trials/condition/hypertension) | 9 | May 11, 2026 |
| [Anxiety Disorders](https://specstream.ai/data/clinical-trials/condition/anxiety-disorders) | 8 | September 10, 2026 |
| [Heart Failure](https://specstream.ai/data/clinical-trials/condition/heart-failure) | 8 | August 12, 2026 |
| [Substance-Related Disorders](https://specstream.ai/data/clinical-trials/condition/substance-related-disorders) | 7 | November 9, 2026 |
| [Pain, Postoperative](https://specstream.ai/data/clinical-trials/condition/pain-postoperative) | 7 | October 30, 2026 |
| [Stroke](https://specstream.ai/data/clinical-trials/condition/stroke) | 7 | October 28, 2026 |
| [Agnosia](https://specstream.ai/data/clinical-trials/condition/agnosia) | 7 | October 13, 2026 |
| [Pulmonary Disease, Chronic Obstructive](https://specstream.ai/data/clinical-trials/condition/pulmonary-disease-chronic-obstructive) | 7 | August 12, 2026 |
| [Insulin Resistance](https://specstream.ai/data/clinical-trials/condition/insulin-resistance) | 7 | July 10, 2026 |
| [Metabolic Syndrome](https://specstream.ai/data/clinical-trials/condition/metabolic-syndrome) | 7 | July 10, 2026 |
| [HIV Infections](https://specstream.ai/data/clinical-trials/condition/hiv-infections) | 7 | July 1, 2026 |
| [Colitis, Ulcerative](https://specstream.ai/data/clinical-trials/condition/colitis-ulcerative) | 7 | June 17, 2026 |
| [Lung Neoplasms](https://specstream.ai/data/clinical-trials/condition/lung-neoplasms) | 7 | August 17, 2025 |
| [Cardiovascular Diseases](https://specstream.ai/data/clinical-trials/condition/cardiovascular-diseases) | 6 | October 28, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 187 | November 9, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 173 | November 4, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 87 | November 9, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 54 | November 9, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 28 | October 30, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 14 | October 22, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 14 | December 16, 2025 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 11 | July 16, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 2 | February 17, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).